(Q35638594)

9 August 2017

title

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study (English)

1 reference

9 August 2017

0 references

1 reference

S Guignard

1

1 reference

9 August 2017

L Gossec

2

1 reference

9 August 2017

C Salliot

3

1 reference

9 August 2017

A Ruyssen-Witrand

4

1 reference

9 August 2017

M Luc

5

1 reference

9 August 2017

M Duclos

6

1 reference

9 August 2017

M Dougados

7

1 reference

9 August 2017

language of work or name

English

0 references

publication date

10 August 2006

1 reference

Annals of the Rheumatic Diseases

9 August 2017

published in

1 reference

9 August 2017

volume

65

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1631-1634

1 reference

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

Why do anti-tumor necrosis factor antibodies work in Crohn's disease?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

Degree, duration, and causes of visual loss in uveitis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

An assessment of clinically useful measures of the consequences of treatment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

Development of Crohn's disease in a patient taking etanercept.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

The treatment of recurrent uveitis with TNF-alpha inhibitors

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798480

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

25 September 2018

1 reference

12 December 2020

Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis

1 reference

12 December 2020

Effect of infliximab on threatening panuveitis in Behçet's disease

1 reference

12 December 2020

[Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study]

1 reference

12 December 2020

Criteria of the classification of spondylarthropathies

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2006.052092

1 reference

9 August 2017

1 reference

9 August 2017

1 reference